Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandu PharmaceuticalsBOM:524703 +1.45%70 Return-on-Tangible-Equity is 0.40% as of Mar. 2026, which is 89% below its 10-year median of 3.58. GuruFocus rates BOM:524703 with a GF Score™ of 70/100 and a GF Value™ of ₹58.60 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 901 Drug Manufacturers companies, Sandu Pharmaceuticals ranks worse than 61.38% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sandu Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was ₹1.7 Mil. Sandu Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹436.5 Mil. Therefore, Sandu Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.40%.
The historical rank and industry rank for Sandu Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
BOM:524703'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1.62 Med: 3.58 Max: 4.55
Current: 4.14
During the past 13 years, Sandu Pharmaceuticals's highest Return-on-Tangible-Equity was 4.55%. The lowest was -1.62%. And the median was 3.58%.
BOM:524703's Return-on-Tangible-Equity is ranked worse than 61.38% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs BOM:524703: 4.14
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sandu Pharmaceuticals Return-on-Tangible-Equity Related Terms
Sandu Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sandu Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524703 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandu Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandu Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandu Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sandu Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.40% mean?
Sandu Pharmaceuticals (BOM:524703) has a Return-on-Tangible-Equity of 0.40% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sandu Pharmaceuticals and its competitors. This is 89% below median its historical median of 3.58. According to the industry distribution chart, Sandu Pharmaceuticals ranks #553 out of 901 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Sandu Pharmaceuticals' Return-on-Tangible-Equity too high?
Sandu Pharmaceuticals' current Return-on-Tangible-Equity of 0.40% is 89% below median its 10-year median of 3.58. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Sandu Pharmaceuticals' value of 0.40% is 94.9% below this industry median. Based on the distribution chart, Sandu Pharmaceuticals ranks #553 out of 901 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandu Pharmaceuticals has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sandu Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sandu Pharmaceuticals ranks #553 out of 901 companies for Return-on-Tangible-Equity. This places Sandu Pharmaceuticals in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. Sandu Pharmaceuticals' value of 0.40% is 94.9% below this benchmark. While the company's 10-year median is 3.58 vs. the industry median of 7.89, Sandu Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandu Pharmaceuticals's current Return-on-Tangible-Equity of 0.40% is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sandu Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandu Pharmaceuticals's current Return-on-Tangible-Equity is 0.40%, which is 89% below median its own 10-year median of 3.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandu Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sandu Pharmaceuticals (BOM:524703) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹58.60, compared to a current price of ₹39.80 — trading 32.1% below its estimated fair value. The current Return-on-Tangible-Equity is 0.40%, which is 89% below median its 10-year median of 3.58 and 94.9% below the Drug Manufacturers industry median of 7.89. Sandu Pharmaceuticals' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sandu Pharmaceuticals (BOM:524703), the current Return-on-Tangible-Equity is 0.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandu Pharmaceuticals (BOM:524703) Overvalued in 2026?
Based on GuruFocus' analysis, Sandu Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹39.80 is trading 32.1% below its estimated GF Value™ of ₹58.60.
GuruFocus considers Sandu Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for BOM:524703:
Return-on-Tangible-Equity: 0.40% (89% below median its 10-year median of 3.58)
GF Value™: ₹58.60 vs. price of ₹39.80 (32.1% below fair value)
Industry Position: 94.9% below the Drug Manufacturers median (#553 of 901)
No single metric tells the full story. See the BOM:524703 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524703 has been successfully added to your 
